Work

Supplementary Figure 1: CTCAE of liver tests for P1CT from The Effect of Hepatic Impairment on Outcomes in Phase I Clinical Trials in Cancer Subjects

Year: 2023

Type: supplementary-materials

Abstract: The peak CTCAE of liver tests for P1CT subjects are shown above. Amongst P1CT, there were higher ALT CTCAEs amongst subjects receiving hepatotoxic agents than non-toxic agents (p<0.01). No differences were seen in CTCAE grades for AST, ALK or total bilirubin based on type of agent.

DOI: 10.1158/1078-0432.22462220

Authors: Aaron S. Mansfield, Michelle A. Rudek, Diana Vulih, Gary L. Smith, Pamela Jo Harris, S. Percy Ivy

Language: English

Topic: Drug-Induced Hepatotoxicity and Protection

Subfield: Pharmacology

Field: Pharmacology, Toxicology and Pharmaceutics

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361920609

Cites:

Cited by:

Related to: 10